GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Vincerx Pharma Inc.
Vincerx Pharma is an oncology company developing next-generation drugs. Its stock price is highly volatile and driven by news of clinical trials. The chart reflects the binary risks and hopes associated with new drug development.
Share prices of companies in the market segment - Cancer blood
Vincerx Pharma is an oncology company developing a new generation of targeted therapies, including biopolymer conjugates, for the treatment of cancer. We have classified it in the "Blood Cancer" category. The chart below shows how investors evaluate innovative approaches to chemotherapy.
Broad Market Index - GURU.Markets
Vincerx Pharma is an oncology company developing next-generation targeted therapies for cancer treatment. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Vincerx shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
VINC - Daily change in the company's share price Vincerx Pharma Inc.
Vincerx Pharma, Inc.'s daily price change reflects the extreme volatility inherent in oncology companies. This metric measures the stock's sensitivity to news about its drug clinical trials, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Cancer blood
Vincerx Pharma is a biopharmaceutical company developing targeted therapies for cancer treatment. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating VINC shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Vincerx Pharma is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Vincerx Pharma Inc.
For Vincerx Pharma, Inc., the year-over-year performance is a story about the development of its new class of oncology drugs. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its "bioconjugates," which deliver toxins to tumors, could lead to a breakthrough in cancer treatment, its primary scientific bet.
Annual dynamics of market capitalization of the market segment - Cancer blood
As an early-stage biotech company, Vincerx is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vincerx Pharma is a biotech company whose value is locked into its cancer drug pipeline. Its shares move in sync with clinical trial news. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Vincerx Pharma Inc.
Vincerx is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its innovative drugs elicits an immediate and strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Vincerx Pharma is a clinical-stage oncology company developing a new generation of targeted therapies, including antibody-drug conjugates, for the treatment of cancer. The chart below illustrates the overall dynamics of the biotech sector, where finding more precise methods of drug delivery to tumors is a key objective.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vincerx Pharma is a biotech company developing targeted therapies for cancer treatment. Its shares move not in sync with the market, but rather based on clinical trial results. Their dynamics reflect the risks and hopes associated with innovative oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Vincerx Pharma Inc.
Vincerx Pharma, a clinical-stage biopharmaceutical company developing drugs to treat blood cancers, exhibits high volatility. Weekly stock performance is driven by news about clinical trials and efficacy data, reflecting the risks and potential of the oncology industry.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Vincerx Pharma shares, like those of the entire oncology biotech sector, are driven by industry-wide news and sentiment. Breakthroughs in targeted therapies or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Vincerx Pharma is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that VINC's performance is largely uncorrelated with the market, driven by its own unique development news.
Market capitalization of the company, segment and market as a whole
VINC - Market capitalization of the company Vincerx Pharma Inc.
Vincerx Pharma's stock chart is a financial map of the next generation of targeted cancer therapy. This biotech company's market cap reflects the hopes for its antibody-drug conjugate (ADC) platform, which delivers chemotherapy directly to tumors. Its performance is a barometer of progress in clinical trials and faith in its ability to create more effective drugs.
VINC - Share of the company's market capitalization Vincerx Pharma Inc. within the market segment - Cancer blood
Vincerx Pharma is a biopharmaceutical company focused on cancer treatment. Its market cap in the oncology sector reflects investors' faith in its innovative approaches. The company's market cap reflects the potential of its developments in one of the most competitive and vital areas of medicine.
Market capitalization of the market segment - Cancer blood
Vincerx Pharma is an oncology company developing a new generation of targeted therapy. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect hopes that new approaches will be more effective in combating cancer cells.
Market capitalization of all companies included in a broad market index - GURU.Markets
Vincerx Pharma is a clinical-stage oncology company developing a new generation of targeted therapies. Its market capitalization is a financial bet on a scientific breakthrough. Its volatile value reflects all the risks and hopes associated with cancer drug development.
Book value capitalization of the company, segment and market as a whole
VINC - Book value capitalization of the company Vincerx Pharma Inc.
For Vincerx Pharma, an oncology company, book value is its equity. The chart below visualizes its financial resources. Its decline reflects planned expenditures on clinical trials of a new generation of targeted cancer drugs.
VINC - Share of the company's book capitalization Vincerx Pharma Inc. within the market segment - Cancer blood
Vincerx Pharma is a clinical-stage biotech company developing cancer drugs. Its value lies in its scientific platform and patents. Its tangible asset share will be minimal, which is typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Cancer blood
Below you can see the overall book value of the biotech sector. Compared to this, Vincerx, which develops targeted cancer therapies, looks "light." Its value lies in its scientific platform and patents, not in its large manufacturing facilities, which is typical for a company focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Vincerx Pharma is a biotech company developing a new generation of targeted cancer therapy. Its assets are not factories, but a scientific platform and patents. The company's balance sheet is the value of its "smart bombs" that deliver the drug precisely to cancer cells, minimizing harm to the rest of the body.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Vincerx Pharma Inc.
Vincerx's balance sheet is its cash and patents. Its market capitalization is a bet on its smart cancer drug technology. The MvsBCap_Co chart shows how much the "dream" of a new generation of chemotherapy is worth compared to the company's current assets.
Market to book capitalization ratio in a market segment - Cancer blood
Vincerx Pharma is a biotech company developing a new generation of targeted therapies for cancer treatment. Its value lies in its scientific platform. The chart shows the speculative valuation of its developments, reflecting investor expectations for the development of more effective and safer drugs.
Market to book capitalization ratio for the market as a whole
Vincerx Pharma develops targeted therapy for cancer treatment. The company's valuation depends almost entirely on progress in clinical trials. This chart is an indicator of investor optimism: the higher the gap between the market and book value, the greater the belief that the company's research will ultimately translate into a successful drug.
Debts of the company, segment and market as a whole
VINC - Company debts Vincerx Pharma Inc.
For Vincerx Pharma, a clinical-stage biopharmaceutical company, debt is a vital resource for R&D. This chart shows how the company is raising capital to develop a new generation of targeted cancer drugs. In this field, debt is funding science on the long journey from the lab to potential approval.
Market segment debts - Cancer blood
Vincerx Pharma is a biotech company developing a new generation of targeted therapies for cancer treatment. While in clinical trials, the company is entirely dependent on its ability to raise capital. This chart illustrates the financial strategy Vincerx is using to advance its innovative drug candidates.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Vincerx Pharma Inc.
Vincerx Pharma is a biotech company developing new treatments for blood cancer. Its operations require significant and ongoing investment. This chart shows the company's dependence on external capital. It indicates high financial risk, which is only justified if its innovative developments are successful.
Market segment debt to market segment book capitalization - Cancer blood
Vincerx Pharma is a clinical-stage biotech company developing a new generation of targeted cancer therapies. This is a capital-intensive field. The chart shows how the company's debt burden to finance its research compares to the market capitalization and risks of the overall oncology sector.
Debt to book value of all companies in the market
Vincerx Pharma (VINC) is a biopharmaceutical company developing targeted therapies for cancer. Being in the clinical stage, the company incurs significant research expenses. This chart shows the overall debt burden of the economy. It helps explain why companies like Vincerx avoid debt to maintain financial flexibility for long R&D cycles.
P/E of the company, segment and market as a whole
P/E - Vincerx Pharma Inc.
This metric for Vincerx Pharma, a clinical-stage biopharmaceutical company, reflects investors' faith in its approach to cancer treatment. There is no price-to-earnings ratio (P/E). The company's valuation is based on the potential of its innovative "smart" drugs, which are designed to more precisely target tumor cells. The chart is sensitive to trial news.
P/E of the market segment - Cancer blood
This is the average P/E for biotech companies. For Vincerx Pharma, which is in clinical development, it serves as a benchmark. It reflects the overall level of investor confidence in oncology, providing context for Vincerx's valuation, which is betting on the success of its next-generation targeted drugs.
P/E of the market as a whole
Vincerx Pharma is an oncology company developing next-generation antibody-drug conjugates (ADCs) and other targeted therapies. Its goal is to create more effective and less toxic treatments. This chart highlights the interest in precision medicine and helps understand whether the market sees a real advantage in Vincerx's technology platform over existing and future ADCs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Vincerx Pharma Inc.
Vincerx Pharma is a biopharmaceutical company developing a new generation of cancer treatments. This chart reflects analysts' expectations for clinical trial results. It doesn't reflect current revenue, but rather shows the potential profit the market is pricing in, betting on the future success of its innovative drugs.
%20P%2FE%20Vincerx%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Vincerx-Pharma-Inc.&v=1772635804749 "Chart of the company's future (projected) P/E Vincerx Pharma Inc.")
Future (projected) P/E of the market segment - Cancer blood
Vincerx Pharma, Inc. is developing a new generation of targeted cancer therapies. This chart shows average expectations for the biotech sector. VINC's position may indicate how investors view its innovative platform and pipeline of drug candidates targeting difficult-to-treat cancers.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772635804780 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Vincerx Pharma is an oncology company developing targeted therapies. Its value is based on the potential of its research. Overall market sentiment, visible on this chart, determines investors' risk appetite and, therefore, the ease of raising capital to continue research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772635804816 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Vincerx Pharma Inc.
Vincerx Pharma is a biopharmaceutical company developing next-generation targeted therapies for cancer treatment. This chart illustrates the complex development process of oncology drugs. Long-term losses are associated with investments in a broad pipeline of developments, while future profits depend on successful clinical trials and partnerships.
Profit of companies in the market segment - Cancer blood
Vincerx Pharma, Inc. is a biotechnology company developing a new generation of targeted therapies for the treatment of blood cancers. Profitability in this oncology segment, as this chart shows, is driven by the need for more effective and less toxic treatments. VINC's goal is to develop drugs that surpass existing treatment standards.
Overall market profit
Vincerx Pharma, which develops targeted therapies for cancer, is a story of science and medicine. Its market capitalization depends on success in clinical trials, not on economic cycles, as this chart illustrates. However, positive market conditions facilitate the significant capital needed to bring innovative oncology drugs to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Vincerx Pharma Inc.
Vincerx Pharma is a biotech company developing targeted therapies for cancer. This chart shows analysts' expectations for future revenue, which are entirely dependent on the success of its drugs in clinical trials. This is a financial assessment of the prospects of its oncology developments.
%20profit%20of%20the%20company%20Vincerx%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Vincerx-Pharma-Inc.&v=1772635804898 "Graph of future (projected) profit of the company Vincerx Pharma Inc.")
Future (predicted) profit of companies in the market segment - Cancer blood
Vincerx Pharma is a biotech company developing a new generation of targeted therapy for the treatment of blood cancers. Its approach is aimed at increasing efficacy and reducing toxicity. This chart shows the profit forecast for the oncology sector, reflecting market expectations for the emergence of more advanced and safer drugs for leukemia and lymphoma.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772635804922 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Vincerx Pharma is a biopharmaceutical company developing cancer treatments. Its key drivers are successful clinical trials, not the economic outlook. However, the overall negative market outlook could complicate raising capital or finding partners to commercialize its targeted therapies, posing a risk for the company.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772635805193 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Vincerx Pharma Inc.
Vincerx Pharma is a clinical-stage oncology company developing highly targeted drugs. It has no sales revenue. This chart shows how the market values the scientific potential of its developments, rather than its current finances. This valuation is essentially a bet that one of its drugs will successfully pass trials and become a blockbuster.
P/S market segment - Cancer blood
Vincerx Pharma is developing a new generation of targeted cancer therapies, combining small molecules with antibodies for precise drug delivery. The chart shows the average revenue estimate for the biotech company. It helps gauge how much investors believe in the potential of its innovative platform compared to the oncology sector average.
P/S of the market as a whole
Vincerx Pharma, Inc. is an oncology company developing a new generation of targeted cancer therapies. Its portfolio is focused on addressing drug resistance. The graph of average market revenue estimates shows that its market capitalization reflects investors' bets on the success of its scientific developments, not on current cash flows.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Vincerx Pharma Inc.
Vincerx Pharma is a clinical-stage biopharmaceutical company developing a new generation of cancer treatments. The chart represents a forward valuation, measuring the company's current market value relative to potential future sales of its innovative drugs if they are approved by regulators.
%20P%2FS%20Vincerx%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Vincerx-Pharma-Inc.&v=1772635805378 "The graph of the company's future (projected) P/S Vincerx Pharma Inc.")
Future (projected) P/S of the market segment - Cancer blood
Vincerx Pharma is developing a new generation of targeted therapies for the treatment of cancer, particularly leukemia and solid tumors. This chart shows the average estimated future sales for oncology companies. It provides an opportunity to assess how investors view the potential of Vincerx's innovative platform and its drug candidates compared to other players.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772635805418 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Vincerx Pharma, Inc. is an oncology company developing a new generation of targeted therapies. Its future depends on the success of clinical trials. This indicator of overall revenue expectations is irrelevant. VINC's entire value lies in its scientific platform and ability to create breakthrough cancer treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772635805425 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Vincerx Pharma Inc.
Vincerx Pharma is a clinical-stage biotech company developing a new generation of targeted therapies for cancer. Its revenue, if present on this chart, typically comes from payments from research partners rather than from sales of finished products. These funds are vital to advancing its research.
Sales of companies in the market segment - Cancer blood
Vincerx Pharma, Inc. is a biopharmaceutical company developing a new generation of targeted cancer therapies. Their innovative platform enables the delivery of highly toxic agents directly to cancer cells, minimizing damage to healthy tissue. This chart shows the sector's total revenue, reflecting progress in creating safer and more effective chemotherapy treatments.
Overall market sales
Vincerx Pharma is a biopharmaceutical company developing targeted therapies for cancer treatment. Its development depends on successful clinical trials and partnerships. The overall economic situation, shown in this chart, affects the availability of capital for funding oncology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Vincerx Pharma Inc.
Vincerx Pharma is a biotech company developing a new generation of targeted cancer therapies. Its future depends on the success of clinical trials of its innovative conjugates and inhibitors. This chart reflects the market's assessment of the likelihood of commercial success for its oncology portfolio.
%20sales%20of%20the%20company%20Vincerx%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Vincerx-Pharma-Inc.&v=1772635805675 "Schedule of future (projected) sales of the company Vincerx Pharma Inc.")
Future (projected) sales of companies in the market segment - Cancer blood
Vincerx Pharma is an oncology company developing a new generation of targeted therapies, including antibody-drug conjugates, for the treatment of blood cancers and solid tumors. This chart illustrates the outlook for the entire hematological oncology sector. Vincerx's future depends on the results of its clinical programs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772635805715 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Vincerx Pharma is developing a new generation of targeted therapy for the treatment of oncological diseases. The company's success depends on the results of clinical trials and partnerships with major pharmaceutical companies. This schedule, reflecting the overall investment climate, influences the willingness of investors and corporations to invest in advanced, but unproven, oncology platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772635805735 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Vincerx Pharma Inc.
Vincerx Pharma is a biopharmaceutical company developing a new generation of targeted therapies for cancer treatment. Its financial performance reflects significant investment in research and development. This chart illustrates how much the company is investing in the development of innovative drugs that have the potential to become profitable in the future.
Market segment marginality - Cancer blood
Vincerx Pharma is a biopharmaceutical company developing a new generation of targeted cancer therapies. This chart shows the average profitability in the oncology sector. The company's innovative platform gives it the potential to develop highly effective drugs and achieve profitability significantly above the industry average in the future.
Market marginality as a whole
Vincerx Pharma, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of oncology. Its financial model is based on raising capital to conduct expensive clinical trials. This total return chart clearly demonstrates that the path to developing a new cancer drug is an investment marathon, not a sprint for current profits.
Employees in the company, segment and market as a whole
Number of employees in the company Vincerx Pharma Inc.
Vincerx Pharma is a biotech company developing a new generation of targeted cancer treatments. In this field, progress is directly dependent on scientific talent. This chart shows the size of the team of scientists and drug developers working to advance its innovative drug portfolio through clinical trials.
Share of the company's employees Vincerx Pharma Inc. within the market segment - Cancer blood
Vincerx Pharma is a biotech company developing a new generation of antibody-drug conjugates for targeted cancer therapy. This is precision oncology. This chart shows the percentage of scientists specializing in this complex biotechnology that Vincerx attracts. It is an indicator of its scientific potential and the concentration of talent in this competitive field.
Number of employees in the market segment - Cancer blood
Vincerx Pharma, Inc. is a biopharmaceutical company developing a new generation of targeted cancer therapies. The chart below shows the company's progress in clinical development. The increase in its research and clinical staff is a positive sign of progress in creating innovative drugs.
Number of employees in the market as a whole
Vincerx Pharma is developing a new generation of targeted cancer treatments. This chart illustrates how the biotech company manages its research capabilities. The growth of its staff, comprised primarily of researchers, is directly related to progress in developing their innovative molecules and expanding their clinical trials program for various tumor types.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Vincerx Pharma Inc. (VINC)
Vincerx Pharma is developing targeted therapies for cancer treatment. Like many biopharmaceutical companies, Vincerx does not yet have mass sales, but it does have a pipeline of promising developments. This chart shows how investors value this pipeline (IP) relative to the small team of highly qualified oncologists and biologists who are driving these developments to success.
%20of%20the%20company%20Vincerx%20Pharma%20Inc.%20(VINC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Vincerx-Pharma-Inc.-VINC&v=1772635806113 "Chart of market capitalization per employee (in thousands of dollars) of the company Vincerx Pharma Inc. (VINC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Vincerx Pharma is a biotech company developing a new generation of targeted therapies for cancer treatment. Its value is entirely dependent on the success of its research and clinical trials. This chart illustrates how investors value the company's intellectual capital per member of its scientific team.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772635806155 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Vincerx Pharma is a biopharmaceutical company developing targeted therapies for cancer treatment. The chart shows their scientific potential. It reflects how the market values their development pipeline and innovative approaches, where the contribution of a small team of researchers can lead to the creation of highly effective drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772635806165 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Vincerx Pharma Inc. (VINC)
Vincerx Pharma is a clinical-stage oncology company developing bispecific drugs. The company is not commercially profitable. This chart shows the net loss (R&D costs) per scientist. This is a venture bet on a future cancer treatment technology that requires significant investment.
%20Chart%20Vincerx%20Pharma%20Inc.%20(VINC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Vincerx-Pharma-Inc.-VINC&v=1772635806167 "Company Profit Per Employee (in thousands of dollars) Chart Vincerx Pharma Inc. (VINC)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Vincerx Pharma is a biotech company developing a new generation of targeted cancer therapies, including bioconjugates. This chart shows the company's per-employee loss during clinical trials. It serves as a benchmark for assessing how intensively the company invests in its research programs per scientist compared to other oncology startups.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772635806184 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Vincerx Pharma is a clinical-stage biotech company developing a new generation of targeted cancer therapies. Like most R&D biotechs, $VINC has no commercial products or revenue. This graph shows a negative value—the investment (loss) per employee dedicated to drug discovery.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772635806196 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Vincerx Pharma Inc. (VINC)
Vincerx Pharma is a biotech company focused on cancer treatment. This chart shows progress in monetizing its research. The increase in revenue per employee will likely be driven by strategic partnerships or licensing agreements with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Vincerx-Pharma-Inc.-VINC&v=1772635806205 "Sales chart per company employee Vincerx Pharma Inc. (VINC)")
Sales per employee in the market segment - Cancer blood
Vincerx Pharma (VINC) is a clinical-stage biotech company developing a new generation of cancer treatments. The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity here would be zero, as the entire staff is focused on R&D, not sales.
Sales per employee for the market as a whole
Vincerx Pharma is a biotech company developing targeted cancer therapies. This metric reflects their current R&D phase. A team of highly qualified researchers is working on future drugs. This graph is important for tracking the transition to commercialization, when revenue from approved drugs begins to cover the cost of R&D personnel.
Short shares by company, segment and market as a whole
Shares shorted by company Vincerx Pharma Inc. (VINC)
Vincerx Pharma (VINC) is an oncology company developing a new generation of drug conjugates (bioconjugates), which are designed to more precisely deliver chemotherapy to cancer cells. This indicator measures skepticism. Those who are "bearish" doubt that their technology will be safer or more effective than existing ones, or that trials will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Vincerx-Pharma-Inc.-VINC&v=1772635806384 "Short Shares Chart for the Company Vincerx Pharma Inc. (VINC)")
Shares shorted by market segment - Cancer blood
Vincerx Pharma is a biopharmaceutical company developing targeted therapies for cancer, including blood cancers. Their approach is aimed at creating safer and more effective drugs. This chart shows the total short bets across the entire oncology biotech sector. It's a barometer of sentiment: if investors are short a sector, they doubt the commercial success of new developments in this field.
Shares shorted by the overall market
Vincerx Pharma is a biotech company focused on oncology. This chart measures overall fear. When investors are pessimistic, they are unprepared for the binary risks of clinical trials. They sell off VINC shares, fearing the company will not have enough capital to complete R&D amid market panic and expensive financing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Vincerx Pharma Inc. (VINC)
Vincerx Pharma (VINC) is a biotech company developing next-generation antibody-drug conjugates (ADCs) and other targeted therapies for cancer treatment. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) on positive early data or "oversold" (below 30) due to capital dilution or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Vincerx-Pharma-Inc.-VINC&v=1772635806557 "RSI 14 indicator chart for the company's stock Vincerx Pharma Inc. (VINC)")
RSI 14 Market Segment - Cancer blood
Vincerx is a "biotech" oncology "sniper." Their platform (bioconjugation) creates "smart bombs" (ADC, SMDC) to attack blood cancer. The "Blood Cancer" sector (biotech) thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is VINC's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Vincerx Pharma (VINC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VINC (Vincerx Pharma Inc.)
Vincerx Pharma is a biotech company developing targeted drugs (conjugates) for cancer treatment. This chart shows the average 12-month analyst forecast, representing their collective speculative bet that the company's R&D pipeline will prove effective in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VINC-Vincerx-Pharma-Inc.&v=1772635806629 "A chart showing analyst consensus forecasts for the expected stock price. VINC (Vincerx Pharma Inc.)")
The difference between the consensus estimate and the actual stock price VINC (Vincerx Pharma Inc.)
Vincerx (VINC) is a biotech company developing a new generation of adjuvant conjugates (ADCs) and a "molecular glue" for cancer treatment. This chart measures the gap between the current price and the consensus target price. It shows how much confidence experts have in their innovative, yet early, R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VINC-Vincerx-Pharma-Inc.&v=1772635806678 "A chart showing the difference between the consensus forecast and the actual stock price. VINC (Vincerx Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Vincerx Pharma is a biotech company developing "smart" drugs (ADCs and "degraders") for the treatment of blood cancers and "cold" tumors. This chart shows overall expectations for the blood cancer sector. It reflects experts' confidence in the success of this "combined" R&D platform.
Analysts' consensus forecast for the overall market share price
Vincerx Pharma (VINC) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market and serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Vincerx Pharma Inc.
Vincerx Pharma is a clinical-stage biotech developing smart drugs (conjugates) for cancer treatment, aiming to improve the efficacy and reduce the toxicity of chemotherapy. This chart is a comprehensive indicator that weighs the scientific potential of their bioconjugation platform, progress in early clinical trials, and the highly competitive nature of targeted oncology.
AKIMA Market Segment Index - Cancer blood
Vincerx Pharma (VINC) specializes in oncology and blood cancer. They develop high-tech drugs (conjugates, Biologics) that target tumor cells. This chart compares their composite index to the average for the blood cancer sector.
The AKIM Index for the overall market
Vincerx Pharma is a biopharmaceutical company developing a modular bioconjugation platform for the creation of small molecule conjugates (SMDCs) for cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative toxin delivery platform compares to overall economic trends.
